Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + abiraterone acetate fixed-dose combination bioavailability and bioequivalence study in metastatic castration-resistant prostate cancer
NL-OMON52439Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of niraparib, abiraterone and prednisone in prostate cancer (PCa) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Steady-state niraparib pharmacokinetics and Steady-state abiraterone acetate pharmacokinetics. Started Dec 2020; status: recruiting.
02
Drugs
niraparibabirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52439.